Please login to the form below
ipilimumab
This page shows the latest ipilimumab news and features for those working in and with pharma, biotech and healthcare.
Merck’s Keytruda meets survival challenge in NSCLC
BMS is trying to gain ground in lung cancer via the CheckMate -227 trial combining Opdivo with its CTLA4 inhibitor Yervoy (ipilimumab), and at AACR reported that the duo almost doubled
Latest news
-
BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer
The US regulator has given the green light to PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced renal cell carcinoma (RCC) patients on
-
Pfizer’s plans for Inlyta go awry with failed adjuvant trial
line RCC, which is due to generate results in 2019 but will also come up against combination therapies from immuno-oncology rivals, not least Opdivo and BMS’CTLA4 inhibitor Yervoy (ipilimumab)
-
Merck’s Keytruda scores in frontline lung cancer yet again
Meanwhile, in February the CHECKMATE-227 trial of BMS’combination of Opdivo and Yervoy (ipilimumab) showed a significant benefit on PFS in first-line NSCLC patients with high TMB, regardless of
-
Incyte/Merck trial failure bodes ill for IDO class
That means for now, PD1/PD-L1 inhibitors as monotherapy, or combined with chemotherapy or CTLA4 drugs like BMS’Yervoy (ipilimumab) “may end up continuing to be the dominant regimens”.
-
AZ pushes back data read-out from MYSTIC lung cancer trial
Meanwhile, a similar approach has been trialled by Bristol-Myers Squibb with Its PD-1 inhibitor Opdivo (nivolumab) and CTLA4 blocker Yervoy (ipilimumab).
More from news
Approximately 9 fully matching, plus 143 partially matching documents found.
Latest Intelligence
-
Pharma deals in February 2015
As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.
-
Pharma deals during July 2014
In this collaboration the focus is Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
CytomX appoints Rachel Humphrey chief medical officer
drug Yervoy (ipilimumab).
-
Jonathan Dickinson joins Ariad from BMS
population. He has previous experience in the commercialisation of cancer drugs, serving for the past three years as BMS' European brand lead for Yervoy (ipilimumab).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Immunotherapy in oncology
This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II ... This led to a changing of the primary clinical
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
-
ASCO 2015: What you missed in Chicago
Bristol-Myers-Squibb redefines Melanoma treatment standards. In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... Patel SP et al Mol Cancer Ther 2015[2] Combined
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Senior Programme Executive
-
Salary TBC
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Account Manager – Med Comms – London
-
Salary TBC
-
Senior Medical Writer
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and benefits
-
Scientific Director
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
Subscribe to our email news alerts
- BenevolentAI raises $115m to fund drug development
- Shire rebuffs Takeda bids, as Allergan bows out
- Abeona Therapeutics names CEO
- Zelluna Immunotherapy appoints chief technology officer
- Spirit Health Group offers new market access consultancy service
- Why heading online for scientific meetings can yield greater HCP engagement
PMHub
M&F Health
M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...
Latest intelligence
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Quick links
Infographics
